EC approves two new regimens of Merck’s KEYTRUDA for metastatic or unresectable recurrent HNSCC

This article was originally published here

This approval is based on findings from the pivotal Phase 3 KEYNOTE-048 trial, in which KEYTRUDA, compared with standard treatment (cetuximab with carboplatin or cisplatin plus 5-FU), demonstrated

The post EC approves two new regimens of Merck’s KEYTRUDA for metastatic or unresectable recurrent HNSCC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply